Brief: Eqs-News Morphosys Presents Updated Tafasitamab Results In Newly Diagnosed Dlbcl Patients From Final Firstmind Analysis

Morphosys AG

11/12/2022 24:01

Dec 10 (Reuters) - Morphosys Ag  MORG.DE :
    * EQS-NEWS: MORPHOSYS PRESENTS UPDATED TAFASITAMAB RESULTS
IN
NEWLY DIAGNOSED DLBCL PATIENTS FROM FINAL FIRSTMIND ANALYSIS AT
ASH 2022
    * EQS-NEWS: MORPHOSYS PRESENTS UPDATED TAFASITAMAB RESULTS
IN
NEWLY DIAGNOSED DLBCL PATIENTS FROM FINAL FIRSTMIND ANALYSIS AT
ASH 2022
    * SENSITIVE ASSAYS TO DETECT MINIMAL RESIDUAL DISEASE HAVE
PROGNOSTIC VALUE AT END OF FIRST-LINE THERAPY
    * FINAL ANALYSIS FROM PHASE 1B FIRSTMIND TRIAL SHOWS NO NEW
SAFETY
SIGNALS

Source text for Eikon:  ID:nEQbPDmKCa 
Further company coverage:  MORG.DE 
 ((Reuters.Briefs@thomsonreuters.com;))